All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
IMAGE study: Isatuximab plus pomalidomide and dexamethasone for RRMM in the real-world setting
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 2
In the retrospective IMAGE study, what was the approximate median progression-free survival observed in the overall efficacy population following treatment with ≥1 dose of isatuximab-Pd?
A
B
C
D
The Multiple Myeloma Hub is pleased to present a visual abstract of a retrospective study by Decaux et al.1 which evaluated real-world outcomes following at least one dose of isatuximab in combination with pomalidomide and dexamethasone (Isa-Pd) for the treatment of relapsed/refractory multiple myeloma (RRMM). The data from these patients were separated by subgroups based on prior lines of therapy as well as refractoriness to lenalidomide and daratumumab.1
The key findings from this study are as follows1:
- A median progression-free survival (PFS) of 12.4 months was observed following treatment with Isa-Pd in the real-world population, comparable to results from clinical trials, including ICARIA-MM (NCT02990338) and APOLLO (NCT03180736).
- Isa-Pd showed a PFS benefit when used as a second-line treatment in patients who were exposed to, but not refractory to, daratumumab, as well as in patients who were refractory to lenalidomide.
- The median PFS for patients refractory to daratumumab was the lowest among all subgroups, at 3.0 months, highlighting the challenges of treating this population.
- The overall response rate (ORR) in the study was 46.3%, with 27.9% of patients experiencing a very good partial response (VGPR).
- Response rates were largely consistent across subgroups, demonstrating the efficacy of Isa-Pd, regardless of prior therapies or refractory status.
- These data align with results from randomized controlled trials, providing further support for the use of Isa-Pd in real-world settings.
- Permanent treatment discontinuation due to toxicity was rare, occurring in 1.3% of patients.
- The safety profile of Isa-Pd was considered manageable, with no new safety concerns identified compared with prior clinical trials.
This educational resource is independently supported by Sanofi. All content was developed by SES in collaboration with an expert steering committee; funders were allowed no influence on the content of this resource.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
